AAPLOG Vice Chair Dr. Susan Bane discusses the potential health risks of abortion drugs like mifepristone on ‘Fox & Friends ...

Cognitive decline can range from mild forgetfulness to serious memory problems like dementia, which can affect a person’s ...

The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug ...

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

A commonly prescribed pain medication—gabapentin—often considered a safer alternative to opioids for those who suffer from low back pain is now under scrutiny after being linked to increased risks of ...

Cognition Therapeutics surges 35% after a positive FDA meeting for Alzheimer’s drug zervimesine. Read more here.

The FDA has updated the labeling for Kisunla™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.

The FDA has approved a label update for Eli Lilly’s Kisunla, an Alzheimer’s treatment, by modifying the recommended dosing schedule for adults with early symptomatic Alzheimer’s disease. The update ...

As Alzheimer's disease progresses beyond the early stages, the behavior changes and emotional impacts of the disease can be ...